Furthermore, lymphoma cells from the peripheral blood of one CD26-positive (moderate) PTCL patient with leukemic phase involvement and from the bone marrow of one CD26-positive (moderate) AITL patient with massive bone marrow involvement were co-cultured as the target cells with CD26 2/3G CAR-T-cells or CD8 2/3G control cells (Figure 6). This evidence concerns the gene CD8A and angioimmunoblastic T-cell lymphoma.